<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52096">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02094430</url>
  </required_header>
  <id_info>
    <org_study_id>FGTW-1004</org_study_id>
    <nct_id>NCT02094430</nct_id>
  </id_info>
  <brief_title>Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency</brief_title>
  <official_title>Clinical Pharmacology, Efficacy and Safety Study of FGTW in Paediatric Patients With Severe Congenital Fibrinogen Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire français de Fractionnement et de Biotechnologies</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>Lebanon: Institutional Review Board</authority>
    <authority>Morocco: Ministry of Public Health</authority>
    <authority>Morocco: Ethics Committee</authority>
    <authority>Turkey: Ethics Committee</authority>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate clinical pharmacology, efficacy and safety of  FGTW in
      pediatric patients with congenital fibrinogen deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Investigator's overall assessment of efficacy of FGTW on hemostasis  using a 4-point scale at the end of each bleeding or surgical episode.</measure>
    <time_frame>6 hours or up to 5 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half life for Fibrinogen antigen and activity</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Participants will be followed for the duration of their participation in the study, an expected average of 1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hypofibrinogenemia, Congenital</condition>
  <condition>Afibrinogenemia, Congenital</condition>
  <arm_group>
    <arm_group_label>FGTW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biological: human fibrinogen concentrate</intervention_name>
    <arm_group_label>FGTW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent form by parents or a legal representative

          -  Age less or equal to 12 years old

          -  Patients with inherited afibrinogenemia or severe inherited hypofibrinogenemia

          -  Negative results on HCG-based pregnancy test for females of childbearing potential
             (presence of menstruation)

        Exclusion Criteria:

          -  Dysfibrinogenemia

          -  Acquired fibrinogen deficiency

          -  Suspected present or past anticoagulation inhibitor

          -  Personal history of venous or arterial thrombosis or thromboembolic event

          -  Co-morbidity with other/unrelated coagulopathies

          -  Administration of any fibrinogen concentrate or fibrinogen containing blood product
             during the last 15 days

          -  Permanent treatment with antithrombotic or anti-platelet agents such as heparins,
             anti-IIa or anti-Xa agents, aspirin, clopidogrel and NSAIDs.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric NEUHART, MD</last_name>
    <phone>33 (0) 1 69 82 70 87</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Necker enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Hôtel Dieu</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital d'enfants - CHU Avicenne</name>
      <address>
        <city>Rabat</city>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculty Ihsan Dogramaci Children's Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Lebanon</country>
    <country>Morocco</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>February 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Afibrinogenemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
